Preventive oncology and oncological prevention

The formation of clinical oncology was accompanied lawful skepticism. For a long time we have heard the optimistic words about oncological prevention possibilities. Then Government of Czechoslovak republic even started controlled experiment called "Oncological action programme" The results were disappointing.

The preventive oncology is a new young medical branch. The founder was Professor Michal Shimkin M.D. from San Jose University California; there are two international organizations for preventive oncology: American Organisation for preventive oncology (ASPO) and International Origination for preventive oncology (ISPO) co-exist.

Fast developing clinical laboratory methods, warning diagnostics, and higher steps of medical knowledge supported conception to look for human tumor in the non-invasive stage. Many clinicians are seriously interested in precanceromatoses in his branch. As a result, his knowleges are rather limited and direct on to his specialty. Preventive oncology has its characteristic features. Studying precarcinomatosis and non-invasive tumors separately disallow research to common features. According to my mind lot of features of precarcinomatosis and still non-invasive tumors, have similar behaviors. As an example see 3 graphs, this supported my theory.

Figure 1

We present the different fields of interest for clinical oncology and preventive oncology.
For instance, let us follow the slowly growing benign polyp in colon. At first, the patient has no difficulties.

Thereinafter the polyp is conductive constipation and patient's difficulties increase. Polyp is still benign and if removing, patient will be healthy. This situation belongs to field of interest of preventive oncology. Now in polyp, malignancy occurs and patient s difficulties getting worse clinical situation changes and are included to clinical oncology field. The critical revolutionary moment, which rate the patient into oncological one we call "the point of invasivity"

The branch of clinical oncology under develops. Other medical branches (cardiology, dermatology, diagnostic fields.) find great progress. This is the reason, why Parisian Charter against cancer arose in February 2000.Anyone can read it on web-sides, I should like to point out two important ideas, connected with preventive oncology: Paris Charter on chapter 6 point out important occurrence. She wrote, "Time is come" to study not only causal appearance of invasive tumors. The same importance is splitting the research and study the appearance of genesis of precanceromatous findings. Very important is to target the point of conversion precanceromatous disease to invasive tumor,

We should point out once again, that any kind consciously omitting cancer prevention is infringement of patient right s and consequently human rights too.

Conclusion:
Sphere preventive oncology is not only oncological prevention. The mission of preventive oncology is to detect still not invasive tumors. Removing non-invasive tumors means often cure the tumor forever.

The purpose of the article is drawing the attention to non-coordinated activity of many clever doctors, which are interested in precanceromatoses on the level of his specialty.

Consequences of it are surprising lack of theoretical knowledges dealing with the beginning tumor process from clinical point of view.

Clinical improvement of non-invasive tumor capture is realistic way to improve clinical results of cancer, despite causal treatment is not clear. Preventive oncology as a sub-branch of clinical oncology follows this way.